Liminatus Pharma (LIMN) Assets (2024 - 2026)

Liminatus Pharma (LIMN) posted Assets of $2.8 million for Q1 2026, up 444.13% sequentially from $512795.0 in Q4 2025.

Liminatus Pharma (LIMN) Assets (2024 - 2026) Analysis & Trends

Liminatus Pharma has reported Assets for 3 years, with the latest figure at $2.8 million in Q1 2026.

Quarterly Assets changed N/A year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (changed N/A YoY) and the FY2025 annual result came in at $512795.0, down 90.52% from the prior year.
Assets rose to $2.8 million in Q1 2026 per LIMN's latest filing, from $512795.0 in the prior quarter.
Over five years, Assets peaked at $5.4 million in Q4 2024 and troughed at $512795.0 in Q4 2025.
A 3-year average of $2.4 million and a median of $1.9 million in 2025 frame the typical range for Assets.
The widest YoY moves for Assets: up 90.52% in 2025, down 90.52% in 2025.
Over 3 years, Assets stood at $5.4 million in 2024, then slumped by 90.52% to $512795.0 in 2025, then jumped by 444.13% to $2.8 million in 2026.
According to Business Quant data, Assets over the past three periods registered $2.8 million, $512795.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	139.47 Bn	131.61 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	86.36 Bn	78.37 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	10.03 Bn
4	Moderna	58.99 Bn	53.85 Bn	52.00 Mn	10.96 Bn
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	9.18 Bn
6	Alnylam Pharmaceuticals	31.74 Bn	28.43 Bn	992.69 Mn	5.56 Bn
7	BioNTech SE	28.01 Bn	9.61 Bn	668.28 Mn	25.60 Bn
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn	2.10 Bn
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	19.82 Bn
10	Liminatus Pharma	262.56 Mn	262.56 Mn	-	3.40 Mn

Download Data